Related Experiment Video
Updated: May 23, 2026
11:08
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Advanced Stage Hodgkin Lymphoma: A Review on Frontline Treatment Advances
1Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute/University of Utah, Salt Lake City, UT.
Cancer Journal (Sudbury, Mass.)
|May 21, 2026
Summary
Hodgkin lymphoma treatment has evolved from often-fatal to largely curable. Modern therapies aim to maintain high efficacy while reducing side effects for better patient outcomes.
Area of Science:
- Oncology
- Hematology
- Clinical Therapeutics
Background:
- Hodgkin lymphoma (HL) was historically fatal, treated with radiation or single-agent chemotherapy.
- Significant advancements have transformed HL into a largely curable malignancy with multiagent chemotherapy.
- Treatment goals have shifted from solely improving cure rates to balancing efficacy with reduced treatment toxicity.
Purpose of the Study:
- To review the evolution of Hodgkin lymphoma treatment strategies.
- To highlight the impact of PET-adapted therapies on treatment efficacy and toxicity.
- To discuss the role of novel therapies in improving outcomes and minimizing side effects.
Main Methods:
- Review of historical and contemporary treatment paradigms for Hodgkin lymphoma.
- Analysis of the impact of PET-adapted escalation and de-escalation strategies.
- Evaluation of outcomes associated with novel therapies like brentuximab vedotin and nivolumab.
Main Results:
- Hodgkin lymphoma treatment has progressed from high mortality to high curability.
- PET-adapted strategies have been crucial in optimizing treatment efficacy and toxicity.
- Novel agents like brentuximab vedotin and nivolumab have significantly improved patient outcomes and reduced toxicity.
Conclusions:
- Modern Hodgkin lymphoma treatment prioritizes maintaining high cure rates while minimizing short- and long-term side effects.
- Novel therapies and collaborative efforts are essential for further improving outcomes in advanced-stage HL.
- The evolution of HL treatment exemplifies progress in balancing oncologic efficacy with patient well-being.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...